Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Non Operating Income (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Non Operating Income for 10 consecutive years, with -$117000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 312.73% to -$117000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58000.0 through Dec 2025, down 38.3% year-over-year, with the annual reading at $58000.0 for FY2025, 38.3% down from the prior year.
  • Non Operating Income for Q4 2025 was -$117000.0 at Akebia Therapeutics, down from -$10000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $1.3 million in Q2 2021, with the low at -$117000.0 in Q4 2025.
  • Average Non Operating Income over 5 years is $329900.0, with a median of $187000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income surged 604.35% in 2022, then tumbled 312.73% in 2025.
  • Over 5 years, Non Operating Income stood at $560000.0 in 2021, then fell by 22.5% to $434000.0 in 2022, then skyrocketed by 51.61% to $658000.0 in 2023, then plummeted by 91.64% to $55000.0 in 2024, then crashed by 312.73% to -$117000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$117000.0, -$10000.0, and -$28000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.